Company intelligence / Profile preview

Nexoft

Melbourne, Victoria, Australianexoftmobile.com ↗

Ownership: Private
Development stage: Other

Overview

Nexvet developed species-specific monoclonal antibodies for chronic pain and inflammatory conditions in companion animals. Its lead candidates advanced to late-stage clinical trials before the company was acquired by Zoetis. The PETisation™ platform enabled rapid translation of mAbs between species.

Therapeutic areas: ImmunologyNeurology
Modalities: Monoclonal antibodyBiologic
Industry: Veterinary

Partnerships

Commercialisation Australia

Beyond the preview

Go deeper on Nexoft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexoft.

Explore the full profile